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OBJECTIVES: Precancerous and cancerous cells can trigger an immune response that may limit tumor development and can be 
used as a prognostic marker. The aims of the present study were to quantify the presence of B and T lymphocytes, macrophages 
and cells expressing inducible nitric oxide synthase (iNOS) in the cervical stroma of women with grade III cervical intraepithelial 
neoplasia (CIN III) or in the intratumoral and peritumoral tissue of women with stage I invasive carcinoma. 
METHODS: Cervical tissue specimens were obtained from 60 women (20 each from control tissues, CIN III and invasive car-
cinomas). The average ages in the control, CIN III and invasive groups were 43.9 (± 4.3), 35.5 (± 9.5), and 50 (± 11.2) years, 
respectively. The specimens were immunohistochemically labeled with antibodies to identify T lymphocytes (CD3), cytotoxic 
lymphocytes (CD8), B lymphocytes (CD20), macrophages (CD68) and iNOS. We evaluated the markers in the stroma above the 
squamocolumnar junction (control), at the intraepithelial lesion (CIN cases), and in the nfiltrating tumor. Two independent observers 
performed the immunohistochemical analysis. 
RESULTS: T lymphocytes, B lymphocytes, macrophages and iNOS were present more frequently (P<0.05) in the stroma of 
peritumoral invasive tumors compared to the controls and intratumoral invasive cancer samples. CD3+ and CD20+ lymphocytes 
were present more frequently in CIN III patients compared to samples from patients with intratumoral invasive cancer (P<0.05).
CONCLUSION: High numbers of T and B lymphocytes, macrophages and iNOS-expressing cells in the peritumoral stroma of 
the invasive tumors were observed. Cell migration appeared to be proportional to the progression of the lesion. 
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INTRODUCTION
Chronic infection of the uterine cervix mucosa by 
human papillomavirus (HPV), most notably HPV16, is 
associated with malignant transformation of keratinocytes 
in metaplastic areas of the transformation zone. Despite 
evidence that HPV is the causative agent of cervical cancer 
and its precursors (squamous intra-epithelial lesions, 
SIL), HPV infection alone is not sufficient for tumor 
development. There is accumulating evidence that tumor 
and virus-infected cells are able to inhibit protective immune 
reactions.1 Although HPV DNA is detected in the majority 
of SIL and uterine cervical carcinomas, the persistence or 
progression of cervical lesions suggest that viral antigens are 
not adequately presented to the immune system.2 Invasive 
epidermoid cancer of the uterine cervix is preceded by 
cervical intraepithelial neoplasia (CIN) associated with 
HPV.3 CIN I is the characteristic response to HPV infection 
and rarely evolves to cancer; instead, it spontaneously 
resolves. In contrast, CIN II and III are potential precursor 
lesions, and approximately 12% of CIN III cases will 
progress to cancer if untreated.4 
Lymphocytes can be divided into B cells, which are 
distinguished by the presence of CD20 on the cell surface, 
or T cells, which are distinguished by the presence of CD3 
on the cell surface. T cells can be further divided into two 
classes: T-helper Lymphocytes (CD4+) and cytotoxic T 576
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Lymphocytes (CD8+). The stroma partially controls tumor 
growth and invasion and has a considerable influence on 
the immune response.5 CD4+ T Lymphocytes, CD8+ T 
Lymphocytes and B Lymphocytes have been observed 
in the stroma of the vaginal and cervical mucosae.6,7 
Lymphocytic infiltrates at neoplasia sites determine the 
clinical prognosis of the infection (persistence, regression or 
progression). Previous studies on dysplastic cervical tissue 
using immunohistochemistry have demonstrated significant 
infiltrates of cytotoxic and auxiliary T and B lymphocytes 
in the stroma below the lesion.6 Several factors determine 
whether IL-12 or IL-4 will predominate and, therefore, 
whether a Th1 or Th2 type immunological response will 
occur in the female genital tract in response to infection 
with a specific infectious agent.8 According to Gonçalves 
and Donadi9, macrophage populations have been found in 
the cervical and vaginal mucosae in the absence of infection 
or inflammation. In CIN II/III patients, increased numbers 
of macrophages have been observed. The presence of these 
cells may indicate regression of the lesion. Currently, the 
role of macrophages in tumor immunology is the subject of 
scientific studies and is considered a promising target for 
future therapy.10 
Nitric oxide (NO) is both a cytotoxic agent and a tumor 
growth promoter. Cytotoxic effects of NO may occur by 
direct damage to DNA subsequent to inhibition of enzymes 
involved in nucleic acid synthesis. In contrast, NO may favor 
tumor dissemination by promoting angiogenesis.11 In a study 
of NO activity, Weissler et al.12 concluded that nitric oxide 
synthase (NOS) levels were elevated in oral squamous cell 
carcinomas. Addicks et al.13 came to a similar conclusion in 
a prostate cancer study. Using an animal model for colon 
carcinoma, Jeannin et al.14 demonstrated that the presence of 
mononuclear cells decreased with increasing production of 
NO by splenic macrophages. Thus, NO production in tumors 
may be responsible for the frequently observed phenomenon 
of tumor-induced immunosuppression. Currently, the role of 
NO in HPV infection and carcinogenesis remains unclear. 
The aims of the present study were to identify and 
quantify the presence of CD3+ and CD8+ T lymphocytes, 
CD20+ B lymphocytes, CD68+ macrophages and inducible 
nitric oxide synthase (iNOS)-expressing cells in the stroma 
of women without neoplastic lesions of the uterine cervix 
and women with CIN III or stage I invasive carcinoma in the 
intratumoral and peritumoral tissue.
MATERIALS AND METHODS 
Samples
Histological sections from the uterine cervix of 60 
women were retrospectively analyzed. The women had 
been patients at the Gynecology and Obstetrics outpatient 
clinic of the Federal University of Triângulo Mineiro 
(UFTM) and had undergone cold-knife conization, loop 
electrosurgical excision, hysterectomy or Wertheim-
Meigs surgical procedures. The project was approved by 
the Research Ethics Committee of Federal University of 
Triângulo Mineiro (UFTM). The histological sections 
were divided into three distinct sets: a control group of 20 
healthy women without any histological evidence of CIN 
or invasive carcinoma who had undergone total abdominal 
hysterectomy due to benign uterine disease (leiomyoma) 
and did not present with cervical abnormalities; 20 women 
with a histological diagnosis of CIN III; and 20 women 
with a histological diagnosis of stage I invasive carcinoma 
according to the classification of the International Federation 
of Gynecology and Obstetrics (FIGO). The surgical 
specimens were obtained from the archives of the Surgical 
Pathology Division and the data used to characterize the 
samples were accessed by reviewing medical files. To 
maintain the confidentiality of the information sources, each 
patient was identified with a number, with numbers 1 to 20 
assigned to women in the control group, 21 to 40, given to 
CIN III patients, and 41 to 60 assigned to invasive carcinoma 
patients. The inclusion criteria for the groups were that 
the women were not pregnant at the time of the biopsy, 
there was no description in the medical files of positive 
serological tests for HIV or any organic condition relating to 
immunosuppression, and the women had no previous history 
of radiotherapy for the treatment of gynecological neoplasia. 
The age range was 35 to 52 years (mean 43.9 ± 4.3 in 
the control group); 22 to 63 years (mean 35.5 ± 9.5) in the 
CIN III group and 26 to 73 years (mean 50 ± 11.2) in the 
invasive carcinoma group. The age at which the subjects 
became sexually active was analyzed in only 19 patients 
in the control group because the medical file of one patient 
indicated that she was a virgin at the time of the surgery. 
The age at sexarche ranged from 12 to 30 years (mean 18.9 
± 4.3) in the control group, 13 to 24 years (17.6 ± 3.3) in the 
CIN III group and 12 to 23 years (16.4 ± 3.2) in the invasive 
carcinoma group. The number of pregnancies ranged from 
0 to 8 (mean 2.75 ± 2) in the control group, 1 to 17 (4.35 
± 3.8) in the CIN III group and 1 to 13 (6.25 ± 3.9) in the 
invasive carcinoma group.
Immunohistochemical analysis
Histological sections (5 mm thick) were cut and 
stained using the hematoxylin-eosin technique. In our 
immunohistochemical study, we used antibodies against 
CD3, CD8, CD20, CD68 and iNOS to characterize the 577
CLINICS 2010;65(6):575-81 Lymphocytes and iNOS in CIN III and invasive cancer
Silva CS et al.
Copyright © 2010 CLINICS
local immune response. The tonsil was used as a control. 
Histological sections (5 μm thick) were cut and placed on 
silanized slides (Sigma, A-3648, St. Louis, MO, USA). 
These slides were stained using the streptavidin-biotin-
peroxidase technique. Briefly, the slides were kept in a glass 
chamber at 56 °C for 24 h before being deparaffinized in 
xylol 3 times for 5 min each, followed by dehydration in 
three baths of pure alcohol and one of 80% alcohol (ethanol) 
for 10 s each. Next, the slides were hydrated in phosphate-
buffered saline (PBS) at pH 7.2 for 5 min. The excess buffer 
solution was immediately removed, and the edge of each 
section was carefully dried using absorbent paper. The slides 
were placed on a tray and 3% oxygenated water was added 
to each section for 10 min to block endogenous peroxidase 
activity. The slides were washed in PBS. The antigens 
were recovered by placing the slides in 5 cytological test 
tubes containing 10 mM citrate buffer solution (pH 6.0). 
The tubes were sealed with aluminum foil and placed in 
a steaming pan (ARNO) for 30 min. The tubes were then 
removed from the pan and placed on the bench to cool. The 
slides were then washed three times with PBS and incubated 
with their respective primary antibodies for 18 h in a damp 
chamber at 3 – 4 °C. The antibodies were diluted in bovine 
serum albumin (Sigma) according to the manufacturer’s 
recommendations. After overnight incubation, the slides 
were placed at room temperature for 15 min, washed in 
PBS and dried as before. Biotinylated secondary antibody 
(DAKO) was added to each slide for 30 min at room 
temperature in a damp chamber. The slides were washed 
in PBS and dried, and the streptavidin-biotin-peroxidase 
complex (DAKO) was added to the slide for 30 min at room 
temperature in a damp chamber. After washing in PBS, the 
slides were developed by adding diaminobenzidine (DAB; 
DAKO) for 5 min. The slides were then washed in running 
water and counterstained using Harris hematoxylin for 2 
s. Finally, the slides were immersed in three baths of pure 
alcohol for 10 s each to remove excess water, followed by 
one bath of phenicated xylol and three baths of xylol for 5 
min each. Coverslips were placed over the samples and they 
were sealed.
To count the lymphoid cells, we used the scoring 
criteria described previously by Sheaff et al.15 Briefly, the 
marked cells were graded as follows: 0 – absence of cells; 
1 – rare cells; 2 – a moderate number of cells; 3 – many 
cells (maximum number of cells found for each analyzed 
marker; see Figure 1). For statistical purposes, we combined 
the 0 and 1 scores and 2 and 3 scores. The cells were 
initially observed at a low magnification (100x) to assess 
the general distribution. The samples were then examined 
in greater detail (magnification: 400x) to obtain the final 
score. Samples from the stroma above the squamocolumnar 
junction, intraepithelial lesion and infiltrating tumor were 
analyzed. The malignant tumors were separated into two 
distinct regions for counting labeled cells: intratumoral and 
peritumoral. Cells in the intratumoral region were considered 
to be located inside the islands of malignant cells. The 
peritumoral region was defined as the area bordering the 
invasive area. Necrotic areas were excluded.
Statistical analysis
For all cases, the analysis was done by two independent 
observers. The agreement between the two observers was 
calculated using the Kappa coefficient. For all markers, the 
Kappa coefficient was 0.83. The final result was obtained 
after joint assessment of discordant cases to produce a single 
value by consensus. The variables were analyzed using 
GraphPad Instat software, version 4.0. The scores were 
compared using the chi-squared test with Yates correction. 
A P value of less than 0.05 was considered statistically 
significant. 
RESULTS
Table 1 presents the results of the histological analysis 
for the markers of T lymphocytes (CD3+), cytotoxic T 
lymphocytes (CD8+), B lymphocytes (CD20+), macrophages 
(CD68+) and iNOS. The number of samples analyzed 
for some markers is less than 20 because no more lesions 
were found in the histological analysis or the marker did 
not work satisfactorily, in which case that patient’s samples 
were excluded. The statistical analysis showed there was a 
significant presence of T lymphocytes (CD3+ and CD8+), 
B lymphocytes, macrophages and iNOS in the stroma of 
peritumoral invasive tumors compared to the controls and 
intratumoral invasive cancer samples. The same trends were 
observed among patients with CIN III, except with respect to 
CD3+ lymphocytes and iNOS. More CD3+ lymphocytes were 
present in CIN III patients than in control patients or those 
with invasive cancer. CD20+ was found more frequently in 
CIN III patients than in those with invasive cancer.
Overall, there was an increase in CD3+ T lymphocytes 
in CIN III patients and in the peritumoral stroma of patients 
with invasive tumors (Figure 2). There was significant 
labeling of all markers analyzed in the peritumoral stromal 
microenvironment; however, all markers were decreased in 
invasive cancer patients compared to CIN III patients.
DISCUSSION
Our data demonstrated a significant increase in CD3+ T 
lymphocytes in CIN III; other cell types did not show this 578
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Table 1 - Distribution of CD3, CD8, CD20, CD68 and iNOS in the cervical stroma of control women, patients with CIN III and patients with invasive 
cervical cancer [n (%)] 
Control  CIN III  Invasive 
Peritumoral** Intratumoral·,··
CD3 6/13 (31.6/68.4) 16/3 (84.2/15.8)* 19/0 (100/0) 1/18 (5.2/94.8)
CD8 4/16 (20/80) 8/11 (42.1/57.9) 16/2 (88.8/11.2) 3/15 (16.7/83.3)
CD20 3/16 (15.7/84.3) 5/14 (26.3/73.7) 18/0 (100/0) 0/18 (0/100)
CD68 1/14 (6.6/93.4) 1/14 (6.6/93.4) 8/7 (53.3/46.7) 1/14 (6.7/93.3)
iNOS 6/14 (30/70) 7/9 (43.7/56.3) 15/5 (75/25) 5/15 (25/75)
* P < 0.002, CD3+ compared with control; ** P < 0.01, all markers compared with CIN III (except CD3 and iNOS) and control; · P < 0.005, all mark-
ers compared with peritumoral markers; ·· P < 0.05, CD3+ and CD20+ compared with CIN III. Note: N for some markers is under 20 because no more 
lesions were found by histological analysis or the staining was insufficient.
Figure 1 -.Samples of stained tissue sections. Histological analysis of tissue stained by CD3 immunohistochemistry shows positive cells (in brown; B, C 
and D) with a score of 0 (A), 1 (B), 2 (C) or 3 (D), as described in the “Materials and Methods” section. Magnification: 200x.579
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trend. This finding is in agreement with previously published 
data.18 Our evaluation revealed no significant difference 
in the number of CD8+ T lymphocytes present in CIN III 
patients compared to controls. Therefore, these cells may 
be helper or regulatory T lymphocytes present in the lesion 
site, as reported in another study, which demonstrated 
that regulatory T cells have a pivotal role in HPV-induced 
lesions.21 The development of effective immunotherapies 
depends on our understanding of the interactions between 
the immune system and the neoplasia and the changes that 
occur during the progression and regression of the lesion. 
The local and systemic immune responses in uterine 
cervical cancer patients and the corresponding precursor 
lesions have previously been studied, as has the migration 
of these cells to the tumor; however, the role specific cell 
types and nitric oxide in the local response is not yet clear. 
The immune response is extremely important in restraining 
these neoplastic cells, and failures in this system may 
lead to cancer progression.16 It has been hypothesized that 
the lesions undergo gradual transformation into tumors 
and that the transformation depends on the type of tumor 
and the mediators of inflammation that are produced 
within the tumor microenvironment.17 Recently, our 
group demonstrated that CIN III patients had more CD3+ 
T lymphocyte infiltrates, a factor that was related to a 
greater chance of recurrence.18 In uterine cervical tumors, 
systemic abnormalities19 or abnormalities in the tumor 
microenvironment may control the local immune response 
and interfere with disease progression.20 
NO has a role in inducing specific and nonspecific 
immunity and an immune response to a variety of 
extracellular parasites and some tumor cells. NO produced 
by iNOS may regulate T cell proliferation, cytokine 
production and apoptosis.22 We found this enzyme in both 
pre-neoplastic lesions and invasive lesions. Data in the 
literature demonstrate that NO derived from macrophages 
may inhibit the lymphocyte response.23 NO produced 
by human tumor cells may, in turn, favor tumor growth 
by paralyzing the function of immune T cells.22,23 Chen 
et al.24 demonstrated that the overexperssion of iNOS in 
cervical cancer patients was associated with decreased 
survival and a greater propensity for metastasis. Another 
study demonstrated that iNOS expression had an inverse 
relationship with macrophage density and tumor progression, 
suggesting that this mediator could modulate the function 
of macrophages and promote tumor progression.25 These 
data suggest that NO may have a role in the differentiation 
or inductive response phase of CD8+ T lymphocytes. 
Therefore, NO may partially inhibit lymphocyte and 
macrophage migration into the tumor, thereby helping the 
neoplastic cells escape the immune response. In addition, 
NO could act in neoplastic cells, as suggested by Kawanishi 
et al,26 who demonstrated that infection by high-risk HPV 
types promotes iNOS-dependent DNA damage, which leads 
to dysplastic changes and carcinogenesis. 
It is intriguing that, although CIN III does not constitute 
an invasive neoplasia, patients with CIN III had statistically 
significant CD3+ T lymphocyte infiltrates in the underlying 
stroma compared to the control group. Moreover, despite the 
large concentration of peritumoral inflammatory infiltrates, 
little or no infiltrate was found inside the tumors. CIN III 
is a systemic disease27 that produces cytokines capable of 
stimulating the migration of CD3+ T lymphocytes. One of 
these cytokines (IL-10) is significantly increased in CIN III 
patients compared to controls.28 Early infiltration of CIN 
lesions by highly cytotoxic effector cells protects against 
progression.29 IL-10 inhibits the production of IL-12 and 
IFN-g, both of which are key to the Th1-type response. 
Inhibition of interferon (IFN)-g production in CIN III 
patients may explain the decreased abundance of CD68+ 
macrophages and iNOS in CIN III patients as compared to 
the control patients, considering that activated macrophages 
are the main inducers of iNOS. Therefore, in CIN III 
patients, the Th2-type response may dominate. In this 
way, the immune response to CIN III would occur through 
production of antibodies and not through cellular immunity. 
If invasive disease develops from CIN III, the large influx 
of peritumoral CD20+ B lymphocytes in these patients may 
be the result of Th2 predominance at an early disease stage. 
The behavior of CD8+ T lymphocytes, macrophages and 
iNOS-expressing cells in patients with invasive disease is 
similar to control patients, and the elevation of CD8+ T 
cells is proportionally lower than the elevation of CD3+ T 
Figure 2 - Distribution of immunohistochemically labeled cells. T lympho-
cytes (CD3+ and CD8+), B lymphocytes (CD20+), macrophages (CD68+) 
and cells that express iNOS from patients in the control group, the CIN III 
group and the group with invasive carcinomas of the uterine cervix in the 
peritumoral stroma and the intratumoral microenvironment were detected 
by immunohistochemistry as described in the “Materials and Methods” 
section. * P < 0.002, CD3+ compared with control; ** P < 0.01, all markers 
compared with CIN III (except CD3 and iNOS) and control; · P < 0.005, 
all markers compared with peritumoral; ·· P < 0.05, CD3+ and CD20+ 
compared with CIN III.580
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lymphocytes. A likely explanation for this finding is that 
from the moment of invasion, macrophages migrate to the 
tumor site and induce iNOS expression, with consequent 
NO production. The induction of NO may inhibit the 
proliferation of CD8+ T lymphocytes. Although there is an 
increase in T and B lymphocytes, macrophages and iNOS 
in the peritumoral area, these cells do not penetrate the 
intratumoral region. 
A high number of B and T lymphocytes were found in 
the stroma of human immunodeficiency virus (HIV+)/CIN 
patients compared to HIV-/CIN patients or normal tissue.30,31 
Our results showed that very little CD20 is present in CIN III 
patient tissue and that CD20 is absent in intratumoral tissue; 
however, it is present at increased levels in the peritumoral 
stroma. Some studies have questioned the importance of B 
lymphocytes and, consequently, the importance of anti-HPV 
antibodies in CIN patients. Petter et al.32 demonstrated that, 
despite the presence of anti-HPV antibodies, HIV+ patients 
had aggressive CIN, suggesting that the cellular immune 
response and not the humoral immune response is important 
for controlling and resolving these neoplasias. 
The local immune response and migration of these cells 
to the tumor has been studied in uterine cervical cancer 
patients and precursor lesions, but the role of specific cells 
and NO in the local response is not yet clear. Apparently, cell 
migration induced by the neoplasia is directly proportional 
to the progression of the lesion, but migration is decreased 
in the intratumoral environment. Moreover, increased iNOS 
expression suggests that large quantities of NO are produced 
during carcinogenesis, principally in the peritumoral area, 
suggesting that this mediator may have an important role 
in carcinogenesis. Taken together, our data demonstrate 
that there are high numbers of CD3+, CD8+ and CD20+ 
lymphocytes, macrophages and iNOS-expressing cells in the 
peritumoral stroma of patients with invasive tumors.
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